We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-9.62%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$327M
AUM Growth
-$243M
Cap. Flow
-$162M
Cap. Flow %
-49.62%
Top 10 Hldgs %
69.58%
Holding
50
New
3
Increased
3
Reduced
–
Closed
9

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$38.8M
2
INZY
Inozyme Pharma
INZY
+$7.95M
3
GOSS icon
Gossamer Bio
GOSS
+$7.06M
4
IOBT
IO Biotech
IOBT
+$4.63M
5
HLVX
HilleVax
HLVX
+$2.81M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$198M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.1M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$9.42M
4
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
+$3.09M
5
ELEV
Elevation Oncology
ELEV
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.2B
$3.45M 1.06%
432,000
– –
PEPG icon
27
PepGen
PEPG
$197M
$3.31M 1.01%
651,050
– –
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$2.41M 0.74%
196,425
– –
RAIN
29
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$1.75M 0.54%
2,034,552
– –
IGMS
30
DELISTED
IGM Biosciences
IGMS
$1.29M 0.4%
154,664
– –
BOLT icon
31
Bolt Biotherapeutics
BOLT
$7.78M
$1.09M 0.33%
52,458
– –
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$1.02M 0.31%
202,348
– –
CYPH
33
Cypherpunk Technologies Inc
CYPH
$73.3M
$831K 0.25%
602,203
– –
VTVT icon
34
vTv Therapeutics
VTVT
$139M
$782K 0.24%
40,888
– –
VIRX
35
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$717K 0.22%
689,709
– –
ALLK
36
DELISTED
Allakos
ALLK
$391K 0.12%
172,089
– –
SNCE
37
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$360K 0.11%
45,000
– –
KLRS
38
Kalaris Therapeutics
KLRS
$96.8M
$177K 0.05%
3,580
– –
KRON
39
DELISTED
Kronos Bio
KRON
$102K 0.03%
78,131
– –
NUVB.WS
40
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.3K ﹤0.01%
133,333
– –
SRZNW icon
41
Surrozen Inc Warrant
SRZNW
$8.86K
$4.11K ﹤0.01%
99,999
– –
ATXS
42
DELISTED
Astria Therapeutics
ATXS
– –
-25,000
Closed -$208K
ELEV
43
DELISTED
Elevation Oncology
ELEV
– –
-830,565
Closed -$1.26M
NVAX icon
44
Novavax
NVAX
$1.31B
– –
-21,244
Closed -$158K
SYRE icon
45
Spyre Therapeutics
SYRE
$9.25B
– –
-35,349
Closed -$398K
TIL icon
46
Instil Bio
TIL
$50.3M
– –
-89,414
Closed -$985K
DBTX
47
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
– –
-801,629
Closed -$3.09M
KDNY
48
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-5,161,888
Closed -$198M
DICE
49
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-202,773
Closed -$9.42M
ISEE
50
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-308,151
Closed -$12.1M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2023 Portfolio in Review

As of Q3 2023, Samsara BioCapital held 50 positions worth $327M, down 43% from $570M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Samsara BioCapital withdrew a net $162M in Q3 2023, closing 9 positions. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in RayzeBio, Inc. Common Stock worth $41M.

  • Samsara BioCapital's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,845,948 shares worth $41M.
  • Samsara BioCapital added most to IO Biotech in Q3 2023, an estimated $4.63M increase.
  • Samsara BioCapital fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $198M.
  • Samsara BioCapital's ten largest holdings make up 70% of its $327M portfolio in Q3 2023.
  • Samsara BioCapital opened 3 new positions and closed 9 in Q3 2023.
  • Samsara BioCapital's portfolio value fell 43% quarter-over-quarter to $327M.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.